Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICOLAS phase II trial of nivolumab with concurrent chemoradiotherapy in stage III non-small cell lung cancer
NL-OMON44704Phase 2Active, not recruiting
- Sponsor
- European Thoracic Oncology Platform
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by European Thoracic Oncology Platform. Primary endpoint: Grade 3 or higher pneumonitis within 6 months after radiotherapy. Started Jun 2016; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON44704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44704.